- Home
- HLIO vs SUPN Comparison
HLIO vs SUPN Comparison
Compare HLIO & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HLIO | SUPN |
|---|---|---|
| Founded | 1970 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 1996 | 2010 |
Fundamental Metrics
Financial Performance| Metric | HLIO | SUPN |
|---|---|---|
| Price | $64.75 | $53.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $65.50 | $61.60 |
| AVG Volume (30 Days) | 323.2K | ★ 748.1K |
| Earning Date | 06-02-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.53% | N/A |
| EPS Growth | ★ 23.93 | N/A |
| EPS | ★ 1.45 | N/A |
| Revenue | $200,727,000.00 | ★ $392,755,000.00 |
| Revenue This Year | $1.86 | $23.19 |
| Revenue Next Year | $5.05 | $17.65 |
| P/E Ratio | $46.71 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.76 | $29.16 |
| 52 Week High | $76.47 | $59.68 |
Technical Indicators
Market Signals| Indicator | HLIO | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 36.98 | 55.71 |
| Support Level | $63.41 | $47.95 |
| Resistance Level | $68.56 | $58.67 |
| Average True Range (ATR) | 3.06 | 2.33 |
| MACD | -1.36 | 0.13 |
| Stochastic Oscillator | 4.64 | 41.87 |
Price Performance
Historical ComparisonAbout HLIO Helios Technologies Inc.
Helios Technologies Inc is a industrial technology company that develops, manufactures, and markets solutions for the hydraulics and electronics markets. It operates under two business segments: Hydraulics and Electronics. The Hydraulics segment designs and manufactures hydraulic cartridge valves, hydraulic quick release couplings as well as engineers complete hydraulic systems. The Electronics segment designs and manufactures customized electronic controls systems and displays for a variety of end markets including industrial and mobile, recreational and health and wellness. It derives maximum revenue from the Hydraulics Segment.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.